Paul, Weiss is advising Ollin Biosciences, Inc., in its acquisition by Johnson & Johnson. Ollin, a privately held clinical-stage biopharmaceutical company, was founded in 2023 to identify and accelerate development of next-generation therapies for vision-threatening diseases. Under the terms of the agreement, Johnson & Johnson will acquire Ollin for $2.2 billion upfront and up to approximately $1.1 billion in additional regulatory and commercial milestone payments. The deal is expected to close by the end of 2026.
The Paul, Weiss team is led by corporate partner Benjamin Goodchild; executive compensation partner Matthew Friestedt and counsel Annie Anderson; antitrust partners Jesse Solomon, Lauren O’Brien and Todd Hahn; intellectual property partner Ian Edvalson and counsel Sean Kwak; tax partner Jim Cole; and litigation partners Geoffrey Chepiga and Blake Rohrbacher, and counsel Audrey Paquet.
Related Insights
November 16, 2026
Paul, Weiss Adds Leading M&A Partner in New York
November 16, 2026